TY - JOUR
T1 - Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator
AU - Berridge, D. C.
AU - Earnshaw, J. J.
AU - Westby, J. C.
AU - Makin, G. S.
AU - Hopkinson, B. R.
PY - 1989
Y1 - 1989
N2 - Fibrinolytic parameters have been monitored in 44 patients undergoing local low-dose intra-arterial thrombolysis for acute peripheral arterial ischaemia. Streptokinase (Sk), at a dose of 5,000 units/hr with 250 units/hr heparin, was used in 23 patients and recombinant tissue plasminogen activator (r-tPA) at a dose of 0.5 mg/hr was used in 21 patients. Successful lysis was seen in 18 (86%) patients following r-tPA and in 15 (65%) patients following streptokinase. There were 4 minor haematomas in each group usually at the catheter entry site. Both agents produced a systemic effect, which was still seen 12 hours post-infusion. However, that produced by r-tPA was delayed and significantly reduced compared to that produced by Sk. These results confirm the relative fibrin specificity of r-tPA. When used as a continuous low-dose intra-arterial infusion, r-tPA offers a significantly lower, potentially safer, systemic effect than conventional therapy with streptokinase.
AB - Fibrinolytic parameters have been monitored in 44 patients undergoing local low-dose intra-arterial thrombolysis for acute peripheral arterial ischaemia. Streptokinase (Sk), at a dose of 5,000 units/hr with 250 units/hr heparin, was used in 23 patients and recombinant tissue plasminogen activator (r-tPA) at a dose of 0.5 mg/hr was used in 21 patients. Successful lysis was seen in 18 (86%) patients following r-tPA and in 15 (65%) patients following streptokinase. There were 4 minor haematomas in each group usually at the catheter entry site. Both agents produced a systemic effect, which was still seen 12 hours post-infusion. However, that produced by r-tPA was delayed and significantly reduced compared to that produced by Sk. These results confirm the relative fibrin specificity of r-tPA. When used as a continuous low-dose intra-arterial infusion, r-tPA offers a significantly lower, potentially safer, systemic effect than conventional therapy with streptokinase.
UR - http://www.scopus.com/inward/record.url?scp=0024535438&partnerID=8YFLogxK
U2 - 10.1055/s-0038-1646575
DO - 10.1055/s-0038-1646575
M3 - Article
C2 - 2501898
AN - SCOPUS:0024535438
SN - 0340-6245
VL - 61
SP - 275
EP - 278
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 2
ER -